Improvement in stroke risk prediction: Role of C-reactive protein and lipoprotein-associated phospholipase A2 in the women's health initiative

International Journal of Stroke

Volumn 9, Issue 7, 2014, Pages 902-909

  Wassertheil Smoller, Sylvia ^a   Mcginn, Aileen ^a   Allison, Matthew ^b   Ca, Tianxi ^c   Curb, David ^d   Eaton, Charles ^e   Hendrix, Susan ^f   Kaplan, Robert ^a   Ko, Marcia ^g   Martin, Lisa W ^h   Xue, Xiaonan ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e BROWN UNIVERSITY   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MAYO CLINIC   (United States)

^h GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Ischemic stroke; Stroke biomarkers

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; LIPID; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; FEMALE; FRAMINGHAM RISK SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STROKE PATIENT; WOMEN'S HEALTH; METABOLISM; MIDDLE AGED; RISK FACTOR; STROKE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84907881877     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2012.00860.x     Document Type: Article

References (16)

1. Mosca L, Benjamin EJ, Berra K etal. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association. Circulation 2011; 123:1243-1262.
2. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38:46-51.
3. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-298.
4. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994; 25:40-43.
5. Thompson A, Gao P, Orfei L etal. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-1544.
6. Ballantyne CM, Hoogeveen RC, Bang H etal. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005; 165:2479-2484.
7. Hays J, Hunt JR, Hubbell FA etal. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003; 13:S18-77.
8. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003; 13:S107-121.
9. Wassertheil-Smoller S, Hendrix SL, Limacher M etal. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289:2673-2684.
10. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172. discussion 207-112.
11. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30:11-21.
12. Zimetbaum PJ, Thosani A, Yu HT etal. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010; 123:446-453.
13. Adams HP Jr, Bendixen BH, Kappelle LJ etal. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35-41.
14. Ridker PM, Danielson E, Fonseca FA etal. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008; 359:2195-2207.
15. Kolodgie FD, Burke AP, Skorija KS etal. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:2523-2529.
16. Serruys PW, Garcia-Garcia HM, Buszman P etal. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118:1172-1182.